{"title": "Langfristige, nicht-interventionelle Beobachtungsstudie nach der Behandlung mit Fate Therapeutics FT500 Zellul\u00e4rer Immuntherapie", "author": null, "url": "https://ichgcp.net/de/clinical-trials-registry/NCT04106167", "hostname": "ichgcp.net", "description": "Probanden, die zuvor an der FT500-101-Studie teilgenommen und eine allogene NK-Zell-Immuntherapie erhalten haben, werden an dieser Langzeit-Follow-up-Studie tei.... Register f\u00fcr klinische Studien. ICH GCP.", "sitename": "Allogene nat\u00fcrliche Killerzelle (NK). bei Melanom und Lymphom und Nierenzellkarzinom - Register f\u00fcr klinische Studien", "date": "2019-09-16", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "Langfristige, nicht-interventionelle Beobachtungsstudie nach der Behandlung mit Fate Therapeutics FT500 Zellul\u00e4rer Immuntherapie\n[Fate Therapeutics](https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Fate%20Therapeutics)\nProbanden, die zuvor an der FT500-101-Studie teilgenommen und eine allogene NK-Zell-Immuntherapie erhalten haben, werden an dieser Langzeit-Follow-up-Studie teilnehmen. Die Probanden werden automatisch in die Studie FT-003 aufgenommen, sobald sie die Interventionsstudie der Eltern abgebrochen oder abgeschlossen haben.\nDer Zweck dieser Studie ist die Bereitstellung von Daten zur Langzeitsicherheit und zum \u00dcberleben von Probanden, die an der Elternstudie teilgenommen haben. Es wird kein zus\u00e4tzliches Studienmedikament verabreicht, aber die Probanden k\u00f6nnen andere Therapien f\u00fcr ihren Krebs erhalten, w\u00e4hrend sie f\u00fcr die langfristige Sicherheit in dieser Studie beobachtet werden.\nStudien\u00fcbersicht\nStatus\nBedingungen\n-\n[Melanom](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Melanoma)\n-\n[Lymphom](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Lymphoma)\n-\n[Nierenzellkarzinom](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Renal%20Cell%20Carcinoma)\n-\n[Geb\u00e4rmutterhalskrebs](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Cervical%20Cancer)\n-\n[Kopf-Hals-Krebs](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Head%20and%20Neck%20Cancer)\n-\n[Hepatozellul\u00e4res Karzinom](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Hepatocellular%20Carcinoma)\n-\n[Magenkrebs](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Gastric%20Cancer)\n-\n[Darmkrebs](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Colorectal%20Cancer)\n-\n[NSCLC](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=NSCLC)\n-\n[Fortgeschrittener solider Tumor](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Advanced%20Solid%20Tumor)\n-\n[Kleinzelliger Lungenkrebs](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Small-cell%20Lung%20Cancer)\n-\n[HER2-positiver Brustkrebs](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=HER2-positive%20Breast%20Cancer)\n-\n[Bauchspeicheldr\u00fcsenkrebs](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pancreas%20Cancer)\n-\n[Urothelkarzinom](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Urothelial%20Carcinoma)\n-\n[Merkelzellkarzinom](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Merkel%20Cell%20Carcinoma)\n-\n[Mikrosatelliten-Instabilit\u00e4t](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Microsatellite%20Instability)\n-\n[Plattenepithelkarzinom](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Squamous%20Cell%20Carcinoma)\n-\n[EGFR-positiver solider Tumor](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=EGFR%20Positive%20Solid%20Tumor)\nIntervention / Behandlung\nDetaillierte Beschreibung\nStudientyp\nEinschreibung (Tats\u00e4chlich)\nKontakte und Standorte\nStudienkontakt\n- Name: Kimberly Musni\n- Telefonnummer: (858) 875-1800\n- E-Mail:\n[clinical@fatetherapeutics.com](mailto:clinical@fatetherapeutics.com?subject=NCT04106167, FT-003, Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy)\nStudieren Sie die Kontaktsicherung\n- Name: Karen Albers\n- Telefonnummer: (858) 875-1800\nStudienorte\n-\nVereinigte Staaten\n-\nCalifornia\n-\nSan Diego, California, Vereinigte Staaten, 92093\n- UCSD Moores Cancer Center\n-\n-\nMinnesota\n-\nMinneapolis, Minnesota, Vereinigte Staaten, 55455\n- University of Minnesota Masonic Cancer Center\n-\n-\nNew Jersey\n-\nHackensack, New Jersey, Vereinigte Staaten, 07601\n- Hackensack University Medical Center\n-\n-\nTexas\n-\nHouston, Texas, Vereinigte Staaten, 77030\n- MD Anderson Cancer Center\n-\n-\nTeilnahmekriterien\nZulassungskriterien\nStudienberechtigtes Alter\nAkzeptiert gesunde Freiwillige\nProbenahmeverfahren\nStudienpopulation\nBeschreibung\nEinschlusskriterien:\n- Probanden, die in einer Interventionsstudie von Fate Therapeutics eine allogene, iPSC-abgeleitete NK-Zelle erhalten haben\n- Probanden, die vor ihrer Studienteilnahme eine Einverst\u00e4ndniserkl\u00e4rung abgegeben haben\nAusschlusskriterien:\n- Unzutreffend\nStudienplan\nWie ist die Studie aufgebaut?\nDesigndetails\nKohorten und Interventionen\n|\n|\nGruppe / Kohorte\n|\n|\nIntervention / Behandlung\n|\n|\nBehandlung mit der FT500 Zellul\u00e4ren Immuntherapie von Fate Therapeutics\nLangzeit-Follow-up von Probanden, die in einer fr\u00fcheren Studie eine allogene, iPSC-abgeleitete NK-Zelle erhalten haben.\n|\n|\nIn dieser Studie wird kein Studienmedikament verabreicht. Patienten, die in einer fr\u00fcheren Studie eine allogene, aus iPSC stammende NK-Zelle erhalten haben, werden in dieser Studie auf langfristige Sicherheit und Wirksamkeit untersucht\nWas misst die Studie?\nPrim\u00e4re Ergebnismessungen\n|\n|\nErgebnis Ma\u00dfnahme\n|\n|\nMa\u00dfnahmenbeschreibung\n|\n|\nZeitfenster\n|\n|\nGesamt\u00fcberleben (OS) nach der Infusion\nZeitfenster: Vom Datum des Studieneintritts bis zum Datum des dokumentierten Todes aus jeglicher Ursache, bewertet bis zu 60 Monate.\n|\n|\nOS definiert als das Intervall zwischen dem Datum der ersten NK-Zell-Infusion und dem Datum des Todes aus irgendeinem Grund\n|\n|\nVom Datum des Studieneintritts bis zum Datum des dokumentierten Todes aus jeglicher Ursache, bewertet bis zu 60 Monate.\nMitarbeiter und Ermittler\nSponsor\nErmittler\n- Studienleiter: Fate Trial Disclosure, Fate Therapeutics\nStudienaufzeichnungsdaten\nHaupttermine studieren\nStudienbeginn (Tats\u00e4chlich)\nPrim\u00e4rer Abschluss (Tats\u00e4chlich)\nStudienabschluss (Tats\u00e4chlich)\nStudienanmeldedaten\nZuerst eingereicht\nZuerst eingereicht, das die QC-Kriterien erf\u00fcllt hat\nZuerst gepostet (Tats\u00e4chlich)\nStudienaufzeichnungsaktualisierungen\nLetztes Update gepostet (Tats\u00e4chlich)\nLetztes eingereichtes Update, das die QC-Kriterien erf\u00fcllt\nZuletzt verifiziert\nMehr Informationen\nBegriffe im Zusammenhang mit dieser Studie\nZus\u00e4tzliche relevante MeSH-Bedingungen\n-\n[Erkrankungen des Verdauungssystems](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Digestive%20System%20Diseases)\n-\n[Pathologische Prozesse](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pathologic%20Processes)\n-\n[Viruserkrankungen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Virus%20Diseases)\n-\n[Infektionen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Infections)\n-\n[Erkrankungen der Atemwege](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases)\n-\n[Neubildungen nach histologischem Typ](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Histologic%20Type)\n-\n[Neubildungen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neoplasms)\n-\n[Lungenkrankheit](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Lung%20Diseases)\n-\n[Urologische Neubildungen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Urologic%20Neoplasms)\n-\n[Urogenitale Neoplasmen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Urogenital%20Neoplasms)\n-\n[Neubildungen nach Standort](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Site)\n-\n[Nierenerkrankungen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Kidney%20Diseases)\n-\n[Urologische Erkrankungen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Urologic%20Diseases)\n-\n[Adenokarzinom](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Adenocarcinoma)\n-\n[Neubildungen, Dr\u00fcsen und Epithelien](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neoplasms%2C%20Glandular%20and%20Epithelial)\n-\n[Erkrankungen des endokrinen Systems](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Endocrine%20System%20Diseases)\n-\n[Neoplasmen des Verdauungssystems](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Digestive%20System%20Neoplasms)\n-\n[Neoplasmen der endokrinen Dr\u00fcse](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Endocrine%20Gland%20Neoplasms)\n-\n[Neubildungen der Atemwege](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Neoplasms)\n-\n[Thoraxneoplasmen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Thoracic%20Neoplasms)\n-\n[Karzinom, bronchogen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Bronchogenic)\n-\n[Bronchiale Neubildungen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Bronchial%20Neoplasms)\n-\n[Neuroektodermale Tumoren](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neuroectodermal%20Tumors)\n-\n[Neoplasmen, Keimzelle und Embryonal](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neoplasms%2C%20Germ%20Cell%20and%20Embryonal)\n-\n[Neubildungen, Nervengewebe](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neoplasms%2C%20Nerve%20Tissue)\n-\n[Nierentumoren](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Kidney%20Neoplasms)\n-\n[DNA-Virusinfektionen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=DNA%20Virus%20Infections)\n-\n[Tumorvirusinfektionen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Tumor%20Virus%20Infections)\n-\n[Lungentumoren](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Lung%20Neoplasms)\n-\n[Erkrankungen der Bauchspeicheldr\u00fcse](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pancreatic%20Diseases)\n-\n[Neuroendokrine Tumoren](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neuroendocrine%20Tumors)\n-\n[Polyomavirus-Infektionen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Polyomavirus%20Infections)\n-\n[Karzinom, Neuroendokrin](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Neuroendocrine)\n-\n[Genomische Instabilit\u00e4t](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Genomic%20Instability)\n-\n[Weibliche Urogenitalerkrankungen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Female%20Urogenital%20Diseases)\n-\n[Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Female%20Urogenital%20Diseases%20and%20Pregnancy%20Complications)\n-\n[Urogenitale Erkrankungen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Urogenital%20Diseases)\n-\n[M\u00e4nnliche Urogenitalerkrankungen](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Male%20Urogenital%20Diseases)\n-\n[Karzinom, Nierenzelle](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Renal%20Cell)\n-\n[Karzinom](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Carcinoma)\n-\n[Kleinzelliges Lungenkarzinom](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Small%20Cell%20Lung%20Carcinoma)\n-\n[Neoplasmen der Bauchspeicheldr\u00fcse](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pancreatic%20Neoplasms)\n-\n[Karzinom, Merkel-Zelle](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Merkel%20Cell)\n-\n[Mikrosatelliten-Instabilit\u00e4t](https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Microsatellite%20Instability)\nAndere Studien-ID-Nummern\n- FT-003\nPlan f\u00fcr individuelle Teilnehmerdaten (IPD)\nPlanen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?\nArzneimittel- und Ger\u00e4teinformationen, Studienunterlagen\nStudiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt\nDiese Informationen wurden ohne \u00c4nderungen direkt von der Website\n[clinicaltrials.gov](https://clinicaltrials.gov) abgerufen. Wenn Sie Ihre Studiendaten \u00e4ndern, entfernen oder aktualisieren m\u00f6chten, wenden Sie sich bitte an [register@clinicaltrials.gov](mailto:register@clinicaltrials.gov). Sobald eine \u00c4nderung auf [clinicaltrials.gov](https://clinicaltrials.gov) implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .\nKlinische Studien zur Melanom\n-\nNCT06099782Noch keine Rekrutierung\n[Eine Studie \u00fcber die von Teilnehmern berichtete Pr\u00e4ferenz f\u00fcr subkutanes Pembrolizumab in Kombination mit Hyaluronidase (MK-3475A) gegen\u00fcber der intraven\u00f6sen Pembrolizumab-Formulierung (MK-3475) bei mehreren Tumortypen (MK-3475A-F11)](https://ichgcp.net/de/clinical-trials-registry/NCT06099782)Melanom | Nierenzellkarzinom | Nicht-kleinzelligem Lungenkrebs\n-\nNCT06093594Noch keine RekrutierungStadium IV Melanom\n-\nNCT06081920Noch keine Rekrutierung\n-\nNCT06075524Rekrutierung\n[Bewertung der Anti-PD-1-Therapie durch \u00dcberwachung der T-Zell-Reaktionen bei Melanomen, Lungenkrebs und anderen Krebsarten](https://ichgcp.net/de/clinical-trials-registry/NCT06075524)Metastasierendes Melanom | Lungenkrebs im Stadium III AJCC v8 | Metastasierendes Lungenkarzinom | Lungenkrebs im Stadium IV AJCC v8 | Lokal fortgeschrittenes b\u00f6sartiges solides Neoplasma | Lokal fortgeschrittenes Melanom | Metastasierendes b\u00f6sartiges festes Neoplasma | Hautmelanom im klinischen Stadium III AJCC v8 | Hautmelanom im klinischen Stadium IV AJCC v8 | Lokal fortgeschrittenes Lungenkarzinom\n-\nNCT06075589Noch keine RekrutierungUveales Melanom\n-\nNCT06073548Noch keine Rekrutierung\n-\nNCT06070012Noch keine Rekrutierung\n-\nNCT06066138Noch keine Rekrutierung\n[Eine Studie zur therapeutischen Arzneimittel\u00fcberwachung basierend auf der Dosierung von Atezolizumab](https://ichgcp.net/de/clinical-trials-registry/NCT06066138)Metastasierendes Melanom | Lokal fortgeschrittenes Melanom | Metastasierendes alveol\u00e4res Weichteilsarkom | Metastasierender nicht-kleinzelliger Lungenkrebs | Metastasierendes hepatozellul\u00e4res Karzinom | Lokal fortgeschrittenes hepatozellul\u00e4res Karzinom | Metastasierter kleinzelliger Lungenkrebs | Lokal fortgeschrittener nicht-kleinzelliger Lungenkrebs | Lokal fortgeschrittenes alveol\u00e4res Weichteilsarkom | Lokal fortgeschrittener kleinzelliger Lungenkrebs\n-\nNCT06060613Rekrutierung\n[Sicherheit und Wirksamkeit von OBX-115 bei fortgeschrittenem/metastasiertem Melanom, das gegen Immun-Checkpoint-Inhibitoren resistent ist](https://ichgcp.net/de/clinical-trials-registry/NCT06060613)Melanom | Metastasierendes Melanom | Tumorhaut\n-\nNCT06054555Rekrutierung\nKlinische Studien zur Allogene nat\u00fcrliche Killerzelle (NK).\n-\nNCT03349502AbgeschlossenAkute myeloische Leuk\u00e4mie\n-\nNCT03937895Abgeschlossen\n-\nNCT03778619UnbekanntRefrakt\u00e4res Non-Hodgkin-Lymphom | Rezidiviertes Non-Hodgkin-Lymphom", "language": null, "image": null, "pagetype": "website", "links": ["https://ichgcp.net/de", "#", "https://ichgcp.net/de", "https://ichgcp.net/", "https://ichgcp.net/es", "https://ichgcp.net/fr", "https://ichgcp.net/it", "https://ichgcp.net/pt", "https://ichgcp.net/ru", "https://ichgcp.net/de/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/de/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/de/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/de/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/de/ich-e-group-of-guidelines", "https://ichgcp.net/de/cro-list", "https://ichgcp.net/de/clinical-trials-registry", "https://ichgcp.net/de/eu-clinical-trials-registry", "https://ichgcp.net/de/pharma-list", "https://ichgcp.net/de/labs", "https://ichgcp.net/de/service-companies", "https://ichgcp.net/de/events", "https://ichgcp.net/de/clinical-trials-registry/publications", "https://ichgcp.net/de/clinical-trials-registry/researchers", "https://ichgcp.net/de/cra-jobs", "https://ichgcp.net/de/publications", "https://ichgcp.net/de/news", "https://ichgcp.net/clinical-trials-registry/NCT04106167", "https://telegram.me/share/url?url=https://ichgcp.net/de/clinical-trials-registry/NCT04106167&text=", "https://twitter.com/intent/tweet?url=https://ichgcp.net/de/clinical-trials-registry/NCT04106167", "https://ichgcp.net/de", "https://ichgcp.net/de/clinical-trials-registry", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Fate%20Therapeutics", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Melanoma", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Lymphoma", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Renal%20Cell%20Carcinoma", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Cervical%20Cancer", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Head%20and%20Neck%20Cancer", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Hepatocellular%20Carcinoma", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Gastric%20Cancer", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Colorectal%20Cancer", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=NSCLC", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Advanced%20Solid%20Tumor", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Small-cell%20Lung%20Cancer", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=HER2-positive%20Breast%20Cancer", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pancreas%20Cancer", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Urothelial%20Carcinoma", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Merkel%20Cell%20Carcinoma", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Microsatellite%20Instability", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Squamous%20Cell%20Carcinoma", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=EGFR%20Positive%20Solid%20Tumor", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Allogeneic%20natural%20killer%20%28NK%29%20cell", "mailto:clinical@fatetherapeutics.com?subject=NCT04106167, FT-003, Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Allogeneic%20natural%20killer%20%28NK%29%20cell", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Fate%20Therapeutics", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Digestive%20System%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pathologic%20Processes", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Virus%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Histologic%20Type", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neoplasms", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Lung%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Urologic%20Neoplasms", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Urogenital%20Neoplasms", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neoplasms%20by%20Site", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Kidney%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Urologic%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Adenocarcinoma", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neoplasms%2C%20Glandular%20and%20Epithelial", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Endocrine%20System%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Digestive%20System%20Neoplasms", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Endocrine%20Gland%20Neoplasms", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Respiratory%20Tract%20Neoplasms", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Thoracic%20Neoplasms", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Bronchogenic", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Bronchial%20Neoplasms", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neuroectodermal%20Tumors", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neoplasms%2C%20Germ%20Cell%20and%20Embryonal", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neoplasms%2C%20Nerve%20Tissue", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Kidney%20Neoplasms", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=DNA%20Virus%20Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Tumor%20Virus%20Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Lung%20Neoplasms", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pancreatic%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Neuroendocrine%20Tumors", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Polyomavirus%20Infections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Neuroendocrine", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Genomic%20Instability", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Female%20Urogenital%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Female%20Urogenital%20Diseases%20and%20Pregnancy%20Complications", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Urogenital%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Male%20Urogenital%20Diseases", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Renal%20Cell", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Carcinoma", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Small%20Cell%20Lung%20Carcinoma", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pancreatic%20Neoplasms", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Carcinoma%2C%20Merkel%20Cell", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Microsatellite%20Instability", "https://clinicaltrials.gov", "mailto:register@clinicaltrials.gov", "https://clinicaltrials.gov", "https://ichgcp.net/de/clinical-trials-registry/NCT06099782", "https://ichgcp.net/de/clinical-trials-registry/NCT06093594", "https://ichgcp.net/de/clinical-trials-registry/NCT06081920", "https://ichgcp.net/de/clinical-trials-registry/NCT06075524", "https://ichgcp.net/de/clinical-trials-registry/NCT06075589", "https://ichgcp.net/de/clinical-trials-registry/NCT06073548", "https://ichgcp.net/de/clinical-trials-registry/NCT06070012", "https://ichgcp.net/de/clinical-trials-registry/NCT06066138", "https://ichgcp.net/de/clinical-trials-registry/NCT06060613", "https://ichgcp.net/de/clinical-trials-registry/NCT06054555", "https://ichgcp.net/de/clinical-trials-registry/NCT03349502", "https://ichgcp.net/de/clinical-trials-registry/NCT03937895", "https://ichgcp.net/de/clinical-trials-registry/NCT03778619", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Wei%2BZhao", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Assistance%2BPublique%2B-%2BH%25C3%25B4pitaux%2Bde%2BParis", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Medical%2BSchool%2BBerlin", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=LiveRNA%2BTherapeutics%2BInc.", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Nanjing%2BPLA%2BGeneral%2BHospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=AstraZeneca", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=M.D.%2BAnderson%2BCancer%2BCenter", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Dicle%2BUniversity%2BSchool%2Bof%2BMedicine%252C%2BDiyarbakir%252C%2BTurkey", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Pirkanmaa%2BHospital%2BDistrict", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Mayo%2BClinic", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Novartis%2BPharmaceuticals", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=National%2BCancer%2BInstitute%2B%2528NCI%2529", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Sismanoglio%2B-%2BAmalia%2BFleming%2BGeneral%2BHospital", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Cairo%2BUniversity", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Middlesex%2BUniversity%2BLondon", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Centre%2Bde%2Bla%2Bmain%2B-%2BCHUV", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Assiut%2BUniversity", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Deutsche%2BGesellschaft%2Bf%25C3%25BCr%2BAllgemein-%2Bund%2BViszeralchirurgie", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=Pfizer", "https://ichgcp.net/de/clinical-trials-registry/research/list?spons=GlaxoSmithKline", "https://ichgcp.net/de/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=HIV%2BInfections", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Coronary%2BArtery%2BDisease", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Asthma", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Minimal%2BChange%2BNephropathy", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Tinea%2Bcruris", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Breast%2BCancer", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Dexmedetomidine%252C%2BEsketamine%252C%2BPostoperative%2BPain%2Band%2BRecovery%2BQuality", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Multi-kinase%2BInhibitors", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Prostate%2BCancer", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Invasive%2BDuctal%2BBreast%2BCarcinoma%2BWith%2BPredominant%2BIntraductal%2BComponent", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Mothers", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Optic%2BNerve", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Musculoskeletal%2BDisorder%2Bof%2Bthe%2BNeck", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Shouldersurgery", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Hypertension", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Pain", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Stroke", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Depression", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Intra-ocular%2BPressure", "https://ichgcp.net/de/clinical-trials-registry/research/list?cond=Obesity", "https://ichgcp.net/de/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Lyndiol%25C2%25AE", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Gemcitabine", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=CD30.CAR-T", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=0.3%2525%2Bhyaluronic%2Bacid%2Beye%2Bdrops", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Chinese%2Bherb%2Bmedicine", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=bardoxolone%2Bmethyl", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=HM781-36B%2Btablets", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=d-amphetamine%2Bsulfate", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Ketamine%2Bhigh-dose", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Cyclophosphamide", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Approved%2BICIs", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Capecitabine", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Bevacizumab", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=FEIBA%2Band%2BNovoSeven", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Prednisone", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Cisplatin", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Docetaxel", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Carboplatin", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Paclitaxel", "https://ichgcp.net/de/clinical-trials-registry/research/list?intr=Dexamethasone", "https://ichgcp.net/de/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/de/cro-list/country/belgium", "https://ichgcp.net/de/cro-list/country/dr_congo", "https://ichgcp.net/de/cro-list/country/czech_republic", "https://ichgcp.net/de/cro-list/country/el_salvador", "https://ichgcp.net/de/cro-list/country/ethiopia", "https://ichgcp.net/de/cro-list/country/greece", "https://ichgcp.net/de/cro-list/country/malta", "https://ichgcp.net/de/cro-list/country/moldova", "https://ichgcp.net/de/cro-list/country/panama", "https://ichgcp.net/de/cro-list/country/portugal", "https://ichgcp.net/de/cro-list/country/saint_lucia", "https://ichgcp.net/de/cro-list/country/saudi_arabia", "https://ichgcp.net/de/cro-list/country/thailand", "https://ichgcp.net/de/cro-list", "https://ichgcp.net/de/cro-list/country/nigeria/company/sgs", "https://ichgcp.net/de/cro-list/country/nigeria/company/54gene_s_clinical_programs_group_cpg", "https://ichgcp.net/de/cro-list/country/nigeria/company/bispharm_clinical", "https://ichgcp.net/de/cro-list/country/nigeria/company/celero", "https://ichgcp.net/de/cro-list/country/nigeria/company/across_global", "https://ichgcp.net/de/cro-list/country/nigeria", "https://ichgcp.net/de/clinical-trials-registry/research/browse/cond_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/cond_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/ord_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/intr_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/intr_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/diet_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/diet_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/spns_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/spns_cat", "https://ichgcp.net/de/clinical-trials-registry/research/browse/locn_alpha_all", "https://ichgcp.net/de/clinical-trials-registry/research/browse/locn_cat", "https://ichgcp.net/de", "https://ichgcp.net/de/guidance-for-industry-investigator-responsibilities-protecting-the-rights-safety-and-welfare-of-study-subjects", "https://ichgcp.net/de/guidance-for-the-notification-of-serious-breaches-of-gcp-or-the-trial-protocol", "https://ichgcp.net/de/national-statement-on-ethical-conduct-in-human-research-2007-updated-2018-nhmrc-australia", "https://ichgcp.net/de/ministerial-ordinance-on-good-clinical-practice-for-drugs-pharmaceuticals-and-medical-devices-agency-japan", "https://ichgcp.net/de/guideline-for-the-notification-of-serious-breaches-of-regulation-eu-no-536-2014", "https://ichgcp.net/de/cro-list", "https://ichgcp.net/de/pharma-list", "https://ichgcp.net/de/labs", "https://ichgcp.net/de/service-companies", "https://ichgcp.net/de/cra-jobs", "https://ichgcp.net/de/clinical-trials-registry", "https://ichgcp.net/de/eu-clinical-trials-registry", "https://ichgcp.net/de/publications", "https://ichgcp.net/de/news", "https://ichgcp.net/about-us-our-mission", "https://ichgcp.net/de/sitemap", "https://ichgcp.net/de/contact-us", "https://ichgcp.net/de/feed", "/privacy", "/disclaimer", "https://ichgcp.net/da/clinical-trials-registry/NCT04106167", "https://ichgcp.net/de/clinical-trials-registry/NCT04106167", "https://ichgcp.net/clinical-trials-registry/NCT04106167", "https://ichgcp.net/es/clinical-trials-registry/NCT04106167", "https://ichgcp.net/fr/clinical-trials-registry/NCT04106167", "https://ichgcp.net/it/clinical-trials-registry/NCT04106167", "https://ichgcp.net/hu/clinical-trials-registry/NCT04106167", "https://ichgcp.net/nl/clinical-trials-registry/NCT04106167", "https://ichgcp.net/no/clinical-trials-registry/NCT04106167", "https://ichgcp.net/pl/clinical-trials-registry/NCT04106167", "https://ichgcp.net/pt/clinical-trials-registry/NCT04106167", "https://ichgcp.net/fi/clinical-trials-registry/NCT04106167", "https://ichgcp.net/sv/clinical-trials-registry/NCT04106167", "https://ichgcp.net/cs/clinical-trials-registry/NCT04106167", "https://ichgcp.net/ru/clinical-trials-registry/NCT04106167", "https://ichgcp.net/ja/clinical-trials-registry/NCT04106167", "https://ichgcp.net/zh/clinical-trials-registry/NCT04106167", "https://ichgcp.net/ko/clinical-trials-registry/NCT04106167", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf", "https://ichgcp.net/pdf/privacy_cookies_policy.pdf", "https://ichgcp.net/pdf/terms_of_service.pdf"]}